15 results about "Enterohemorrhagic e coli" patented technology

The invention discloses a kit for simultaneously detecting 16 food-borne pathogenic bacteria. Each group of probes is designed based on bacterial classification, virulence gene specificity or serotype marks of the pathogenic bacteria; a group A probe vibrio detection group is used for detecting vibrio cholerae universal type, vibrio cholerae O1 serotype, vibrio cholerae O139 serotype and vibrio parahaemolyticus; the B group of probe invasive enterobacteriaceae pathogen group is used for detecting escherichia coli O157: H7, shigella, salmonella and yersinia small intestine; the C group probe escherichia coli pathotype detection group is used for detecting enterotoxigenic escherichia coli ETEC, enteroinvasive escherichia coli EIEC, enteroaggregative adherent escherichia coli EAEC and pathogenic escherichia coli EPEC; and the D group of probes are used for detecting campylobacter jejuni, campylobacter colons, listeria monocytogenes and enterohemorrhagic escherichia coli EHEC in the campylobacter and toxin type pathogen group.

The invention discloses a multiple qPCR (quantitative polymerase chain reaction) detection reagent for detecting neonatal gastrointestinal infection pathogens. The kit comprises specific primers and probes for detecting enterohemorrhagic escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, streptococcus agalactiae, klebsiella pneumoniae, staphylococcus epidermidis, beta hemolytic streptococcus, salmonella, rotavirus and adenovirus. According to the invention, different fluorescently-labeled probes are utilized to add specific primers and probes of multiple pathogens into a reaction system to detect multiple targets at the same time, and the method has the advantages of good specificity, high sensitivity, short detection period, capability of simultaneously detecting multiple pathogens, rapidness, simplicity, convenience and economy; a convenient method is provided for rapid detection of pathogens causing neonatal gastrointestinal infection, and the kit has important significance in epidemiological research, clinical early molecular diagnosis and the like.

The invention discloses an anti-type II Shiga toxin monoclonal antibody and a related product and application thereof, the monoclonal antibody can specifically bind to Stx2, Stx2a and Stx2b and has high binding activity, in addition, the monoclonal antibody can significantly prolong the survival time of a mouse infected with enterohemorrhagic escherichia coli and significantly improve the survival rate of the mouse, and the monoclonal antibody can be used for preparing a monoclonal antibody for resisting type II Shiga toxin. The invention provides a new strategy for early diagnosis of enterohemorrhagic Escherichia coli infection related diseases and development of drugs for prevention or treatment of enterohemorrhagic Escherichia coli infection related diseases, and has a good clinical application prospect.

The invention relates to methods for detecting the presence or absence of an enterohemorrhagic Escherichia coli (EHEC) in a sample and / or identifying said EHEC. The invention further relates to such methods comprising subjecting the sample or protein therein to mass spectrometry to obtain mass spectrometry data, comparing the obtained mass spectrometry data with reference data for at least one EHEC strain with a specific serotype and optionally one or more non-EHEC strains and detecting the presence or absence of the EHEC.

The present invention relates to a DNA construct that codes for a fusion protein comprising at least two enterohemorrhagic Escherichia coli antigens, for example, the antigens Int280, EspB, EspA, Stx2B, EspD, combinations or fragments thereof, vectors, fusion protein, immunisation methods and vaccines. The coded antigens can be fused Int280 and EspB of enterohemorrhagic Escherichia coli, forming a fusion protein with or without a connecting sequence between the two. The fused antigens can show the amino acid sequence SEQ ID No. 3 or SEQ ID No. 4 and are coded by the nucleotide sequence in SEQ ID No. 1 and SEQ ID No. 2. The construct can also comprise a signal sequence and a binding sequence for binding to the membrane of bacteria.

The invention relates to a polyclonal antibody of enterohemorrhagic Escherichia coli Intimin protein as well as a preparation method and application of the polyclonal antibody, and the polyclonal antibody of the enterohemorrhagic Escherichia coli Intimin protein can specifically recognize the enterohemorrhagic Escherichia coli Intimin protein and has relatively high titer; according to the present invention, with the enterohemorrhagic Escherichia coli Intimin protein polyclonal antibody, the infection process of enterohemorrhagic Escherichia coli can be deeply understood through the enterohemorrhagic Escherichia coli Intimin protein polyclonal antibody, such that the hereditary basis and the molecular mechanism of the enterohemorrhagic Escherichia coli infection host cell can be further researched; the method has double values for understanding pathogenesis and developing prevention and control means.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to application of tamibarotene and a Toll-like receptor stimulant in preparation of a vaccine adjuvant. The invention relates to a tamibarotene vaccine adjuvant composition, which is prepared by combining tamibarotene and a Toll-like receptor (TLRS) agonist, and the tamibarotene vaccine adjuvant composition is prepared by combining tamibarotene and the TLRs agonist. The composition can significantly promote antigen-specific mucosal immune response, and especially has a prominent effect on gastrointestinal mucosa parts; meanwhile, an organism can be effectively stimulated to generate specific systemic humoral immunity and cellular immune response. In an enterohemorrhagic Escherichia coli challenge model experiment, the vaccine adjuvant composition can be used for remarkably improving the immune protection effect induced by the recombinant intimin antigen, and a new effective strategy is provided for vaccine research and development and immune enhancement.

The present invention relates to a gelling reaction medium for the detection, identification and / or isolation of at least one Shiga toxin-producing Escherichia coli strain, the reaction medium comprising:-at least one toxin-inducing agent,-at least one agglutination conjugate, -a nanoparticle comprising at least one specific binding partner of STX1 and / or at least one specific binding partner of STX2 conjugated to the nanoparticle,-a concentration gradient of a compound for inhibiting non-target bacteria. The invention also relates to related methods of detecting and / or isolating Shiga toxin-producing Escherichia coli that may be present in a sample containing intestinal bacteria.

The present disclosure relates primer pairs, probes, kits, and methods of use thereof to detect virulent strains of Shiga toxin-producing Escherichia coli (E. coli) (STEC).

The present invention relates to a gelling reaction medium for the detection, identification, and / or isolation of at least one Shiga toxin-producing Escherichia coli strain, comprising: - at least one toxin inducer; - at least one agglutination conjugate containing at least one specific binding partner of STX1 and / or at least one specific binding partner of STX2, conjugated to nanoparticles; and - a concentration gradient of compounds for inhibiting non-target bacteria. The present invention also relates to related methods for detecting and / or isolating Shiga toxin-producing Escherichia coli that are likely to be present in a sample containing enterobacteria.

The present invention relates to a method for detecting and identifying at least one Shiga toxin-producing Escherichia coli (STEC) that may be present in a sample containing enterobacteria, said method comprising the following steps:-lysing the sample in order to lyse the STEC, thereby obtaining a solution comprising the nucleic acids thereof; -contacting said nucleic acid solution with primers to allow amplification of at least the stx1 and / or stx2 genes or gene fragments; -if amplified to at least one of the stx1 and / or stx2 genes or gene fragments, placing a portion of the sample onto an agar reaction medium comprising: at least one toxin inducer, at least one agglutination conjugate, at least one agglutination conjugate, at least one poison inducer, at least one poison inducer, at least one poison inducer, at least one poison inducer, at least one poison inducer, and at least one poison inducer. The binding partner is formed by at least one binding partner specific to the STX1 protein and / or at least one binding partner specific to the STX2 protein, and the binding partner is coupled with the nanoparticle; -detecting and confirming the presence of at least one STEC by the presence of a halo on the agar around said STEC.

This invention discloses a monoclonal antibody against type II Shiga toxin, its related products, and applications. The monoclonal antibody can specifically bind to Stx2, Stx2a, and Stx2b and has high binding activity. In addition, the monoclonal antibody can significantly prolong the survival time of mice infected with enterohemorrhagic Escherichia coli and significantly improve their survival rate. This invention provides a new strategy for the early diagnosis of enterohemorrhagic Escherichia coli-related diseases and the development of drugs for the prevention or treatment of enterohemorrhagic Escherichia coli-related diseases, and has good prospects for clinical application.

The invention relates to methods for detecting the presence or absence of an enterohemorrhagic Escherichia coli (EHEC) in a sample and / or identifying said EHEC. The invention further relates to such methods comprising subjecting the sample or protein therein to mass spectrometry to obtain mass spectrometry data, comparing the obtained mass spectrometry data with reference data for at least one EHEC strain with a specific serotype and optionally one or more non-EHEC strains and detecting the presence or absence of the EHEC.

The present invention discloses a broad lysis spectrum enterohemorrhagic Escherichia coli phage and its application. The phage strain has a deposition number of CCTCC NO: M 20211003 and was deposited in the China Center for Type Culture Collection of Wuhan University on August 10, 2021. It is classified and named as enterohemorrhagic Escherichia coli O157:H7 phage vB_EcoM_SQ17, Enterohemorrhagic Escherichia coli O157:H7 phage vB_EcoM_SQ17; it has a high bactericidal ability against enterohemorrhagic Escherichia coli, can lyse enterohemorrhagic Escherichia coli O157:H7, and can also lyse other pathogenic Escherichia coli. The present invention has a good antibacterial effect on enterohemorrhagic Escherichia coli in both whole milk and skim milk.